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Abstract

Results

Discussion

Cardiovascular disease (CVD) is one of the most
prevalent illnesses worldwide and the leading cause of
death in the U.S. Obstructive sleep apnea (OSA) has been
found to be a risk factor correlated to CVD. Therefore, the
following clinical question arises: [P] In an adult patient
(35-75 years old) diagnosed with OSA, [I] does the use of
CPAP [C: compared to patients with OSA who do not use
CPAP] [O]decrease the risk and/or progression of CVD?

1. Baratta F, Pastori D, Bucci T, et al. Long-term prediction of adherence to continuous positive air pressure therapy for
the treatment of moderate/severe obstructive sleep apnea syndrome. Sleep Medicine. 2018;43:66-70.
doi:10.1016/j.sleep.2017.09.032
Ø Cohort study of 483 participants designed to investigate the predictors of long-term non-compliance of CPAP in
patients with newly diagnosed moderate to severe OSA over 6 years
2. Baratta F, Pastori D, Fabiani M, et al. Severity of OSAS, CPAP and cardiovascular events: A follow-up study. Eur J Clin
Invest. 2018;48(5):e12908. doi:10.1111/eci.12908
Ø Cohort study of 483 participants designed to investigate the association between OSA severity and major
cardiovascular and cerebrovascular events and to investigate the potential impact of CPAP therapy on
cardiovascular outcomes
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Ø Randomized controlled trial of 15,325 participants designed to test the efficacy of CPAP in reducing rate of
cardiovascular events among patients with OSA
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Ø Randomized controlled trial of 249 participants designed to assess the influence of early nasal CPAP treatment on
cardiovascular recurrences and mortality in patients with first-ever ischemic stroke and moderate-severe OSA
during a 5 year follow-up
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Ø Randomized controlled trial of 679 participants designed to asses the effect of CPAP on prevention of new
vascular events in patients with stroke and OSA at least 6 weeks after the ictus
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an acute stroke with OSA according to gender and age

3/6 are considered adequately valid while the
remaining 3/6 are considered marginal

Introduction
Cardiovascular Disease
Ø Includes hypertension, stroke, heart failure, coronary
artery disease (CAD) and atrial fibrillation
Ø Risk Factors: hyperlipidemia, family history of
hypertension, obesity, smoking and diabetes
Obstructive Sleep Apnea
Ø Described as repetitive episodes of apnea, or
cessation of breathing, during sleep
Ø Risk Factors: obesity, oropharyngeal abnormalities,
increased neck circumference, male sex and smoking
Ø Treatment: Continuous Positive Airway Pressure
(CPAP)
Intervention
Ø Decreases apnea and hypopnea during sleep,
reducing negative effects on cardiovascular system

Methods
Literature search conducted in November 2019 using:
Ø PubMed
Ø EBSCO
Ø Google Scholar
Search terms: “continuous positive airway pressure AND
cardiovascular AND obstructive sleep apnea”
Inclusion Criteria
Ø Randomized controlled trials within last 5 years
Ø Human subjects
Ø Written in English
Exclusion Criteria
Ø Subject size with n < 100
Ø Total trial length < 12 months
Ø Subject age range outside 35-75 years old
Ø Studies without a controlled trial
Ø Studies containing only one gender

Strengths
Ø 5/6 include factor of CPAP compliance
Ø 4/6 statistically significant for increased survival of
patients
Ø Consistency of criteria used in majority of articles
offers stronger correlation
Ø Sample sizes
Ø No studies are considered inadequate
Limitations
Ø Role of comorbidities in disease
Ø Bias varies throughout studies
Ø Variation of trial duration
Ø Recruitment methods
Future Research
Ø Improve screening methods for OSA
Ø Continue long-term research on effects of
treatment of OSA on progression of CVD
Ø Cost effectiveness

Table 1. Comparison of Study Designs
Study

Design

1

Retrospective
Cohort

2

Retrospective
Cohort

3

Double Blind RCT

4

Prospective NonBlind RCT

Total N
301
434
2,687

235

Age Range
OSA Criteria
(years)
46-68

AHI≥15

43-68

AHI levels

45-75

SatO2 drops
³ 4%

54-75

AHI³20

Duration
(months)

CPAP Compliance

Outcome
Measurements

74.8

4 hrs per night/5 days per
week

Vascular events;
survival

81.3

4 hrs per night/5 days per
week

Vascular events;
survival

44

3 hrs during 1-week runin with sham CPAP

Vascular events;
survival

24; 68

4 hrs per night/70% of
days

Vascular events;
survival
AHI; vascular events
Survival

5

Single Blind RCT

70

41-65

AHI>15

12

4 hrs per night/70% of
days

6

Quantitative

220

56-74

N/A

12

N/A

RCT = randomized control trial; AHI = apnea/hypopnea events/h; N/A = not applicable

Conclusion
Statistically significant increase in overall survival
through use of long-term CPAP
Not enough evidence to support a change in current
clinical practice. However, it can be suggested for
better screening practices for OSA can be
implemented.
Encouragement of CPAP treatment due to mask
discomfort and financial responsibility are still major
factor that will impact future use in clinical practice.

